MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Significant Increase in Short Interest

by · The Cerbat Gem

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totaling 7,182,036 shares, a growth of 24.3% from the December 31st total of 5,776,842 shares. Currently, 12.7% of the company’s stock are sold short. Based on an average trading volume of 5,630,446 shares, the short-interest ratio is presently 1.3 days. Based on an average trading volume of 5,630,446 shares, the short-interest ratio is presently 1.3 days. Currently, 12.7% of the company’s stock are sold short.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. The Goldman Sachs Group cut MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and increased their price target for the stock from $8.00 to $10.00 in a report on Wednesday, January 14th. Zacks Research cut shares of MoonLake Immunotherapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 20th. UBS Group set a $24.00 price target on shares of MoonLake Immunotherapeutics in a research note on Friday, January 9th. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday. Finally, BTIG Research raised MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Friday, January 9th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $25.77.

Check Out Our Latest Stock Report on MoonLake Immunotherapeutics

Insider Buying and Selling

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 130,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the transaction, the chief executive officer owned 2,948,577 shares of the company’s stock, valued at $44,464,541.16. The trade was a 4.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kristian Reich sold 130,000 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the completion of the transaction, the insider directly owned 72,908 shares in the company, valued at $1,099,452.64. The trade was a 64.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 402,908 shares of company stock valued at $5,987,162. Insiders own 12.02% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. FNY Investment Advisers LLC purchased a new position in shares of MoonLake Immunotherapeutics in the 3rd quarter worth approximately $28,000. Bank of America Corp DE boosted its stake in MoonLake Immunotherapeutics by 64.7% in the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock valued at $32,000 after acquiring an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in MoonLake Immunotherapeutics by 115.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after purchasing an additional 3,166 shares in the last quarter. Covestor Ltd purchased a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at $46,000. Finally, BNP Paribas Financial Markets raised its stake in shares of MoonLake Immunotherapeutics by 18.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after buying an additional 1,158 shares during the last quarter. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Stock Performance

MoonLake Immunotherapeutics stock traded down $0.31 during trading on Wednesday, hitting $15.06. The stock had a trading volume of 1,387,164 shares, compared to its average volume of 3,348,684. The stock’s 50 day moving average is $14.66 and its two-hundred day moving average is $27.47. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75. The stock has a market cap of $967.32 million, a price-to-earnings ratio of -4.54 and a beta of 1.21. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25.

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same period last year, the firm earned ($0.56) earnings per share. As a group, analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

About MoonLake Immunotherapeutics

(Get Free Report)

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.

Further Reading